Sheu J R, Lin C H, Peng H C, Teng C M, Huang T F
Pharmacological Institute, College of Medicine, National Taiwan University, Taipei.
Jpn J Cancer Res. 1993 Oct;84(10):1062-71. doi: 10.1111/j.1349-7006.1993.tb02802.x.
In this study, we examined the effect of triflavin, an Arg-Gly-Asp (RGD)-containing snake venom peptide, on human cervical carcinoma (HeLa) cell- and B16-F10 mouse melanoma cell-induced platelet aggregation (TCIPA) in heparinized platelet-rich plasma. TCIPA appears to play an important role in the development of certain experimental tumor metastases. Two ADP-scavenging agents, apyrase (10 U/ml) and creatine phosphate (CP) (5 mM)/creatine phosphokinase (CPK) (5 U/ml) completely inhibited B16-F10 TCIPA, but hirudin (5 U/ml) had no effect. In contrast, apyrase and CP/CPK did not inhibit HeLa TCIPA while hirudin completely inhibited it. Furthermore, HeLa cells initially induced platelet aggregation and then blood coagulation at a later stage. In addition, HeLa cells shortened, in a concentration-dependent manner, the recalcification time of normal as well as factor VIII- and IX-deficient human plasma, but did not affect the recalcification time of factor VII-deficient plasma. This suggests that HeLa TCIPA occurs via activation of the extrinsic pathway, probably owing to tumor cell expression of tissue factor-like activity. HeLa cell-induced thrombin generation was confirmed by detection of amidolytic activity towards a chromogenic substrate, S-2238 (H-D-Phe-Pip-Arg-p-NA). Triflavin and GRGDS inhibited, in a dose-dependent manner, TCIPA caused by either cell line. On a molar basis, triflavin was 10,000-30,000 times more potent than GRGDS in this regard. Moreover, monoclonal antibodies raised against glycoprotein (GP) IIb/IIIa complex (i.e., 7E3 and AP2) and against GP Ib (i.e., AP1) completely inhibited HeLa TCIPA. 7E3 and AP2 inhibited B16-F10 TCIPA by up to 80% whereas AP1 showed only 30% inhibition of B16-F10 TCIPA. In conclusion, the inhibitory effect of triflavin on HeLa and B16-F10 TCIPA may be mediated principally by the binding of triflavin to the fibrinogen receptor associated with GP IIb/IIIa complex on the platelet surface. However, GP Ib is also involved in HeLa TCIPA as thrombin formation is the key factor in triggering platelet aggregation caused by HeLa cells.
在本研究中,我们检测了含精氨酸 - 甘氨酸 - 天冬氨酸(RGD)的蛇毒肽三黄素对肝素化富血小板血浆中人类宫颈癌(HeLa)细胞和B16 - F10小鼠黑色素瘤细胞诱导的血小板聚集(TCIPA)的影响。TCIPA似乎在某些实验性肿瘤转移的发展中起重要作用。两种ADP清除剂,腺苷三磷酸双磷酸酶(10 U/ml)和磷酸肌酸(CP)(5 mM)/肌酸磷酸激酶(CPK)(5 U/ml)完全抑制了B16 - F10细胞诱导的血小板聚集,但水蛭素(5 U/ml)没有作用。相反,腺苷三磷酸双磷酸酶和CP/CPK没有抑制HeLa细胞诱导的血小板聚集,而水蛭素完全抑制了它。此外,HeLa细胞最初诱导血小板聚集,随后在后期诱导血液凝固。另外,HeLa细胞以浓度依赖的方式缩短了正常以及缺乏因子VIII和IX的人血浆的复钙时间,但不影响缺乏因子VII的血浆的复钙时间。这表明HeLa细胞诱导的血小板聚集是通过外源性途径的激活发生的,可能是由于肿瘤细胞表达了组织因子样活性。通过检测对发色底物S - 2238(H - D - Phe - Pip - Arg - p - NA)的酰胺水解活性证实了HeLa细胞诱导的凝血酶生成。三黄素和GRGDS以剂量依赖的方式抑制由两种细胞系引起的TCIPA。在摩尔基础上,在这方面三黄素比GRGDS的效力高10000 - 30000倍。此外,针对糖蛋白(GP)IIb/IIIa复合物(即7E3和AP2)和针对GP Ib(即AP1)产生的单克隆抗体完全抑制了HeLa细胞诱导的血小板聚集。7E3和AP2抑制B16 - F10细胞诱导的血小板聚集达80%,而AP1仅显示对B16 - F10细胞诱导的血小板聚集有30%的抑制作用。总之,三黄素对HeLa和B16 - F10细胞诱导的血小板聚集的抑制作用可能主要是通过三黄素与血小板表面与GP IIb/IIIa复合物相关的纤维蛋白原受体结合来介导的。然而,GP Ib也参与HeLa细胞诱导的血小板聚集,因为凝血酶的形成是触发HeLa细胞引起的血小板聚集的关键因素。